New RSV vaccine trial aims to protect vulnerable adults in japan
NCT ID NCT07543380
First seen May 09, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This study tests an experimental RSV vaccine in 130 adults aged 18 to 59 in Japan who have health conditions that raise their risk of severe RSV. The vaccine is designed to help the body build defenses against the virus. Researchers will monitor safety and immune response for about 2 months after a single shot.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fukuwa Clinic
Chuo-ku, Tokyo, 104-0031, Japan
-
Nihonbashi Sakura Clinic
Chuo-ku, Tokyo, 103-0025, Japan
-
Tenjin Sogo Clinic
Fukuoka, 810-0021, Japan
-
Tokyo-Eki Center-building Clinic
Chuo-ku, Tokyo, 103-0027, Japan
-
Tsuchiura Beryl Clinic
Tsuchiura, Ibaraki, 300-0062, Japan
Conditions
Explore the condition pages connected to this study.